Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 May;26(5):1263-9.

Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate

Wilburn E Reddick  1 , John O Glass, Kathleen J Helton, James W Langston, Xiaoping Xiong, Shengjie Wu, Ching-Hon Pui
Affiliations
Review

Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate

Wilburn E Reddick et al. AJNR Am J Neuroradiol. 2005 May.

Abstract

Background and purpose: An effective treatment for acute lymphoblastic leukemia (ALL), intravenous (IV) methotrexate (MTX) has a notable toxic effect on the CNS, with leukoencephalopathy (LE) being the most common form. The purpose of this study was to use objective quantitative MR imaging to prospectively assess potential risk factors on the temporal evolution of LE in patients treated for ALL.

Methods: We evaluated the longitudinal prevalence of LE in 45 children treated for ALL in a single institutional protocol including seven courses of IV MTX and no cranial irradiation. Differences in signal intensity on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images between hyperintense regions and normal-appearing genu were used to quantitatively detect LE. Cox proportional regression was used to estimate the effect of covariates (e.g., sex, MTX dose, age at diagnosis) on the prevalence of LE. After influential factors were identified, a generalized linear model was determined to predict the probability of LE in new patients. The model was necessary to facilitate statistical testing between examinations.

Results: Increasing exposure, which corresponding to more courses and higher doses of IV MTX, influenced the prevalence of LE. The prevalence of LE was significant reduced approximately 1.5 years after the completion of IV MTX.

Conclusion: Higher doses and more courses of IV MTX placed patients at a higher risk for LE; many of the changes resolved after the completion of therapy. The effect of these changes on neurocognitive functioning and quality of life in survivors remains to be determined.

PubMed Disclaimer

Figures

F<sc>ig</sc> 1.
Fig 1.
T1-, T2-, and proton density–weighted and FLAIR images (left to right) from a typical examination. LE can be seen in the white matter posterior to the ventricles.
F<sc>ig</sc> 2.
Fig 2.
Cumulative risk for LE as a function of time since diagnosis. Solid line represents patients in the standard- and high-risk treatment arm; dashed line, those in the low-risk treatment arm.
F<sc>ig</sc> 3.
Fig 3.
Observed prevalence of LE in patients in the standard- or high-risk arm (gray bars) and patients in the low-risk arm (black bars) of the treatment protocol.
F<sc>ig</sc> 4.
Fig 4.
Predicted probability of LE according to the general linear model for patients in the standard- or high-risk arm (gray bars) and patients in the low-risk arm (black bars) of the treatment protocol.
F<sc>ig</sc> 5.
Fig 5.
FLAIR images from a typical examination. Left to right, Sections after one course, four courses, and seven courses of high-dose IV MTX therapy; at the end of therapy; and at 2 years after the completion of therapy. A, Transient LE. Although the first image is normal, the second and third show LE, which resolves by the fourth and remains normal on the final image. B, Persistent LE. First image is normal, but all others, including the 2-year follow-up image, show LE.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pui C-H, Relling MV, Downing JR. Mechanisms of disease acute lymphoblastic leukemia. N Engl J Med 2004;350:1535–1548 - PubMed
    1. Shuper A, Stark B, Kornreich L, Cohen IJ, Avrahami G, Yaniv I. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J 2002;4:1050–1053 - PubMed
    1. McIntosh S, Fischer DB, Rothman SG, Rosenfield N, Lobel JS, O’Brien RT. Intracranial calcifications in childhood leukemia. J Pediatr 1977;91:909–913 - PubMed
    1. Peylan-Ramu N, Poplack DG, Pizzo PA, Adornato BT, Di Chiro G. Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978;298:815–818 - PubMed
    1. Ochs JJ, Parvey LS, Whitaker JN, et al. Serial cranial computed-tomography scans in children with leukemia given two different forms of central nervous system therapy. J Clin Oncol 1983;1:793–798 - PubMed

Publication types

Substances